JGC
DMAA

J. Goldman & Co’s Drugs Made In America Acquisition Corp DMAA Stock Holding History

J. Goldman & Co’s Portfolio DMAA Stock Details DMAA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-500,000
Closed -$5.19M – 931
2025
Q4 		$5.19M Hold
500,000
– – 0.14% 191
2025
Q3 		$5.13M Buy
+500,000
New +$5.13M 0.13% 195

Other funds holding DMAA

KIM
Karpus Investment Management Pittsford, New York $3.48B AUM 10.49% 1-Year Est. Return
FTCM
First Trust Capital Management Chicago, Illinois $1.72B AUM 70.69% 1-Year Est. Return
MSU
Mizuho Securities USA New York $6.2B AUM 35.46% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return
WCMNY
Westchester Capital Management (New York) Valhalla, New York $2.04B AUM 31.03% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $6.07B AUM 34.81% 1-Year Est. Return
WAM
Wolverine Asset Management Chicago, Illinois $11.4B AUM 5.66% 1-Year Est. Return
HCM
Highbridge Capital Management New York $3.09B AUM 31.22% 1-Year Est. Return
AC
Aristeia Capital Greenwich, Connecticut $7.69B AUM 15.5% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

J. Goldman & Co's DMAA Position: Q1 2026 in Review

J. Goldman & Co sold out of Drugs Made In America Acquisition Corp (DMAA) in Q1 2026, closing a stake of 500,000 shares — an estimated $5.19M sold.

J. Goldman & Co first reported a position in DMAA in Q3 2025 and held it in 2 quarters. The position peaked at $5.19M in Q4 2025. 39 funds tracked by Wall St. Rank hold DMAA as of Q1 2026.

  • J. Goldman & Co reported no remaining Drugs Made In America Acquisition Corp position as of Q1 2026 after selling out during the quarter.
  • J. Goldman & Co sold 500,000 Drugs Made In America Acquisition Corp shares in Q1 2026, an estimated $5.19M.
  • J. Goldman & Co first reported a position in Drugs Made In America Acquisition Corp in Q3 2025 and held it in 2 quarters.
  • J. Goldman & Co's Drugs Made In America Acquisition Corp position peaked at $5.19M in Q4 2025.
  • 39 funds tracked by Wall St. Rank held Drugs Made In America Acquisition Corp as of Q1 2026.

Based on J. Goldman & Co's 13F filing for Q1 2026, filed 15 May 2026.